Study Meetings definition

Study Meetings means meetings regarding the Study, including, but not limited to, investigator, study coordinator and/or results meetings. Study Meetings are standard practice in conducting clinical studies and may occur before, during and after the Study. The purpose of meetings before and during the study is to ensure that the Study is properly planned and conducted in a harmonised way in accordance with GCP. Meetings after the Study usually are about sharing the outcome and results of the Study.

Study Meetings means meetings regarding the Study, including, but not limited to, Principle Investigator, study coordinator and/or results meetings. Study Meetings are standard practice in conducting clinical studies and may occur before, during and after the Study. The purpose of meetings before and during the study is to ensure that the Study is properly planned and conducted in a harmonised way in accordance with GCP. Meetings after the Study usually are about sharing the outcome and results of the Study. “Study Site Staff” means all those employees, students, agents or others who are engaged in the conduct of the Study including any sub/co-investigators.” 2. Attendance at Study Meetings Principal Investigator and Study Site Staff may be invited to attend and participate in Study Meetings. To the extent that Principal Investigator and Study Site Staff attend a Study Meeting, the Parties agree that there will be no additional compensation for attendance or participation at such Study Meeting. If the Principal Investigator or Study Site Staff are retained by PPD to perform services at the meetings, the terms and obligations of such services will be subject to a separate agreement. PPD intends to conduct Study Meetings in compliance with the applicable laws, regulations and codices of the Czech Republic. Consistent with Pharmaceutical Industry codices and Sponsor’s Global Policy External Interaction available at xxx.xxxxxxxxxxx.xxx, PPD may offer modest hotel accommodation, meals and transportation to and from the Study Meeting (collectively, “Accommodation”) to Principal Investigator and Study Site Staff attending Study Meetings. The value of such Accommodation may be disclosed pursuant to applicable laws and regulations. Principal Investigator on behalf of itself and Study Site Staff acknowledge and confirm that their attendance at a Study Meeting directly relates to their participation in the Study and is not an inducement to, or in return for, future or past prescribing, purchasing, use, preferential formulary status or dispensing of any Sponsor product. When attending Study Meetings Principal Investigator on behalf of itself and Study Site Staff represent and warrant that their attendance is authorized by their employer and will not cause them to be in non-compliance with or in breach of any policy, procedure or contract. 15.

Study Meetings means meetings regarding the Study, including, but not limited to, investigator, study coordinator and/or results meetings. Study Meetings are standard practice in conducting clinical studies and may occur before, during and after the Study. The purpose of meetings before and during the Study is to ensure that the Study is properly planned and conducted in a harmonized way in accordance with GCP. Meetings after the Study usually are about sharing the outcome and results of the Study.

Examples of Study Meetings in a sentence

• ELEMENT Ineffective=1 Minimally Effective=2 Effective=3 Highly Effective=4 Participation in Team Meetings Attribute: Team meetings are department, IEP and Child Study Meetings The Speech Language Pathologist does not attend team meetings and does little to be a meaningful participant in the student assistant team process.

• ELEMENT Ineffective=1 Minimally Effective=2 Effective=3 Highly Effective=4 Participation in Team Meetings Attribute: Team meetings are department, IEP and Child Study Meetings The Occupational Therapist does not attend team meetings and does little to be a meaningful participant in the student assistant team process.

• Institution represents and warrants that Investigator and Study Site Staff attendance on Study Meetings is authorized and will not cause them to be in non- compliance with or in breach of any policy, procedure or contract.

• ELEMENT Ineffective=1 Minimally Effective=3 Highly Effective=4 Effective=2 Participation in Team Meetings Attribute: Team meetings are department, IEP and Child Study Meetings The Speech Language Pathologist does not attend team meetings and does little to be a meaningful participant in the student assistant team process.

• When attending Study Meetings Investigator on behalf of itself and Study Site Staff represent and warrant that their attendance is authorised by their employer and will not cause them to be in non-compliance with or in breach of any policy, procedure or contract.

• Reimbursement of expenses incurred while attending Study Meetings can only be paid after this Addendum is fully executed.

• The Lead Trial Site shall reimburse or pay for reasonable pre-approved expenses for attendance at the Study Meetings upon receipt of documentation.

• The Other Trial Site agrees that no additional compensation shall be due hereunder for the Sub-Investigator’s or any other Personnel’s participation in any Study Meetings.

• ELEMENT Ineffective=1 Minimally Effective=3 Highly Effective=4 Effective=2 Participation in Team Meetings Attribute: Team meetings are department, IEP and Child Study Meetings The Occupational Therapist does not attend team meetings and does little to be a meaningful participant in the student assistant team process.

• READ AND ACKNOWLEDGED by Principal Investigator Signature Name: Title: Principal Investigator Date: Schedule A to Appendix 2 Protocol Procedures Covered in Appendix 2 [Attach Protocol Study Plan or Protocol procedure spreadsheet with prices and Standard of Care Procedures identified] Appendix 3 Accommodation Expenses at Study Meetings Expense Reimbursement Guidelines This attachment provides guidance on Expense Reimbursements that can be charged back to AstraZeneca.